Location History:
- North Haven, CT (US) (1987 - 1988)
- Madison, CT (US) (1999)
Company Filing History:
Years Active: 1987-1999
Title: Wallace Haigh: Innovator in Glucose Transporter Research
Introduction
Wallace Haigh is a notable inventor based in Madison, Connecticut, recognized for his contributions to the field of glucose transporter research. With a total of four patents to his name, Haigh has made significant strides in understanding insulin resistance and its implications for diabetes treatment.
Latest Patents
Haigh's latest patents include the development of a glucose transporter vesicle aminopeptidase. This aminopeptidase is a crucial component of GLUT4-containing vesicles in their natural state and plays a role in cleaving insulin. The claimed protein has an apparent molecular weight of approximately 110 kD in its deglycosylated form, with a predicted molecular weight of 117,239 Daltons. It features specific amino acid sequences, including Phe-Ala-Ala-Thr-Gln-Phe-Glu-Pro-Leu-Ala-Ala (SEQ ID NO: 1) and Ile-Leu-Gln-Asn-Gln-Ile-Gln-Gln-Gln-Thr-Arg-Thr-Asp-Glu-Gly-Xaa-Pro-Xaa-Met (SEQ ID NO: 2). Additionally, it reacts with antibodies produced against the peptide identified as SEQ ID NO: 1. The patent also claims modulators of the aminopeptidase's activity and methods for treating syndromes of insulin resistance, including diabetes, through the administration of such modulators.
Career Highlights
Throughout his career, Wallace Haigh has worked with prominent companies such as Molecular Diagnostics, Inc. and Bayer Corporation. His work has significantly impacted the understanding of glucose transport mechanisms and their relevance to metabolic disorders.
Collaborations
Haigh has collaborated with esteemed colleagues, including William J. Knowles and Vincent T. Marchesi, contributing to advancements in his field.
Conclusion
Wallace Haigh's innovative work in glucose transporter research and his patents reflect his commitment to addressing critical health issues such as insulin resistance and diabetes. His contributions continue to influence the scientific community and pave the way for future advancements in treatment options.